ARLEO, ANDREA
ARLEO, ANDREA
DIPARTIMENTO DI SCIENZE MEDICHE E CHIRURGICHE
Assegnisti
Balancing Affinity, Selectivity, and Cytotoxicity of Hydrazone-Based G-Quadruplex Ligands for Activation of Interferon β Genes in Cancer Cells
2022 Marzano S.; Miglietta G.; Morigi R.; Marinello J.; Arleo A.; Procacci M.; Locatelli A.; Leoni A.; Pagano B.; Randazzo A.; Amato J.; Capranico G.
Topoisomerase I poison-triggered immune gene activation is markedly reduced in human small-cell lung cancers by impairment of the cGAS/STING pathway
2022 Jessica Marinello, Andrea Arleo, Marco Russo, Maria Delcuratolo, Francesca Ciccarelli, Yves Pommier, Giovanni Capranico.
Stemness underpinning all steps of human colorectal cancer defines the core of effective therapeutic strategies
2019 Visioli A.; Giani F.; Trivieri N.; Pracella R.; Miccinilli E.; Cariglia M.G.; Palumbo O.; Arleo A.; Dezi F.; Copetti M.; Cajola L.; Restelli S.; Papa V.; Sciuto A.; Latiano T.P.; Carella M.; Amadori D.; Gallerani G.; Ricci R.; Alfieri S.; Pesole G.; Vescovi A.L.; Binda E.
Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience
2017 Mangia, Alessandra; Susser, Simone; Piazzolla, Valeria; Agostinacchio, Ernesto; De Stefano, Giulio; Palmieri, Vincenzo; Spinzi, Giancarlo; Carraturo, Immacolata; Potenza, Domenico; Losappio, Ruggero; Arleo, Andrea; Miscio, Maria; Santoro, Rosanna; Sarrazin, Christoph; Copetti, Massimiliano
Sustained Virological Responses (SVR) of 97% in Genotype 2 (GT-2) Patients with F3/4 Stage of Fibrosis Treated with Sofosbuvir (SOF) and Weight-Based Ribavirin (RBV): A Real Life, Single Centre Experience
2016 Mangia, A.; Arleo, A.; Piazzolla, V.; Santoro, R.; Petruzzellis, D.; Miscio, M.; Squillante, M.M.
The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin
2016 Mangia A.; Arleo A.; Copetti M.; Miscio M.; Piazzolla V.; Santoro R.; Squillante M.M.
The Combination of Daclatasvir and Sofosbuvir for Curing Genotype 2 Patients who cannot Tolerate Ribavirin
2016 Mangia, A.; Arleo, A.; Copetti, M.; Miscio, M.; Piazzolla, V.; Santoro, R.; Squillante, M.M.
The current treatment of hepatitis C
2016 Arleo A.; Mangia A.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Balancing Affinity, Selectivity, and Cytotoxicity of Hydrazone-Based G-Quadruplex Ligands for Activation of Interferon β Genes in Cancer Cells | Marzano S.; Miglietta G.; Morigi R.; Marinello J.; Arleo A.; Procacci M.; Locatelli A.; Leoni A.;... Pagano B.; Randazzo A.; Amato J.; Capranico G. | 2022-01-01 | JOURNAL OF MEDICINAL CHEMISTRY | - | 1.01 Articolo in rivista | JMC.pdf; jm2c00772_si_002.pdf |
| Topoisomerase I poison-triggered immune gene activation is markedly reduced in human small-cell lung cancers by impairment of the cGAS/STING pathway | Jessica Marinello, Andrea Arleo, Marco Russo, Maria Delcuratolo, Francesca Ciccarelli, Yves Pomm...ier, Giovanni Capranico. | 2022-01-01 | BRITISH JOURNAL OF CANCER | - | 1.01 Articolo in rivista | BJC.pdf |
| Stemness underpinning all steps of human colorectal cancer defines the core of effective therapeutic strategies | Visioli A.; Giani F.; Trivieri N.; Pracella R.; Miccinilli E.; Cariglia M.G.; Palumbo O.; Arleo A....; Dezi F.; Copetti M.; Cajola L.; Restelli S.; Papa V.; Sciuto A.; Latiano T.P.; Carella M.; Amadori D.; Gallerani G.; Ricci R.; Alfieri S.; Pesole G.; Vescovi A.L.; Binda E. | 2019-01-01 | EBIOMEDICINE | - | 1.01 Articolo in rivista | 1-s2.0-S2352396419302889-main.pdf; file supplementari.zip |
| Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience | Mangia, Alessandra; Susser, Simone; Piazzolla, Valeria; Agostinacchio, Ernesto; De Stefano, Giuli...o; Palmieri, Vincenzo; Spinzi, Giancarlo; Carraturo, Immacolata; Potenza, Domenico; Losappio, Ruggero; Arleo, Andrea; Miscio, Maria; Santoro, Rosanna; Sarrazin, Christoph; Copetti, Massimiliano | 2017-01-01 | JOURNAL OF HEPATOLOGY | - | 1.01 Articolo in rivista | - |
| Sustained Virological Responses (SVR) of 97% in Genotype 2 (GT-2) Patients with F3/4 Stage of Fibrosis Treated with Sofosbuvir (SOF) and Weight-Based Ribavirin (RBV): A Real Life, Single Centre Experience | Mangia, A.; Arleo, A.; Piazzolla, V.; Santoro, R.; Petruzzellis, D.; Miscio, M.; Squillante, M.M. | 2016-01-01 | JOURNAL OF HEPATOLOGY | - | 1.06 Abstract in rivista | - |
| The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin | Mangia A.; Arleo A.; Copetti M.; Miscio M.; Piazzolla V.; Santoro R.; Squillante M.M. | 2016-01-01 | LIVER INTERNATIONAL | - | 1.01 Articolo in rivista | - |
| The Combination of Daclatasvir and Sofosbuvir for Curing Genotype 2 Patients who cannot Tolerate Ribavirin | Mangia, A.; Arleo, A.; Copetti, M.; Miscio, M.; Piazzolla, V.; Santoro, R.; Squillante, M.M. | 2016-01-01 | JOURNAL OF HEPATOLOGY | - | 1.06 Abstract in rivista | - |
| The current treatment of hepatitis C | Arleo A.; Mangia A. | 2016-01-01 | MINERVA GASTROENTEROLOGICA E DIETOLOGICA | - | 1.01 Articolo in rivista | - |